Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Jemincare Starts Phase I China Trial of COVID-19 Antibody
Jemincare Group of
JMB2002 is derived using the company's phage-to-yeast platform, which allows researchers to pinpoint candidates from over 10 billion antibody molecules in 19 days.
Jemincare focuses on R&D of novel drugs with a pipeline aimed at diseases in cancer, central nervous system, respiratory system, cardiovascular and cerebrovascular systems. The company has recruited over 400 R&D scientists in five research centers for products that include biologics, novel small molecules, novel drug delivery methods, generic drugs and traditional Chinese medicines.
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China